BCLAF1 has been identified as a promising candidate for diagnostic and therapeutic development because experimental studies show it contributes to cisplatin resistance in non-small cell lung cancer (NSCLC).102. This evidence concerns the gene BCLAF1 and non-small cell lung carcinoma.